Report: GLP-1s Dethrone Skincare Shifting Medical Aesthetic Spend

Weight-loss medications continue to impact the medical aesthetics industry. GLP-1s surpassed skincare as the top consumer spend category, according to a new report from Guidepoint Qsight. 

Guidepoint Qsight found patients are focusing on the overall wellness journey, prioritizing bundling aesthetic treatments including injectables, weight-loss medication, skincare, and hormone therapy. 

The report, “What Patients Bundle Most: Unpacking Aesthetic Purchasing Trends,” draws on millions of actual patient transactions from thousands of aesthetic practices nationwide, finding: 

• GLP-1s now appear in 10% of body contouring visits.
• Skincare adds up to 45% more revenue to skin rejuvenation visits and is often the only reason for coming in. 
• Neurotoxin-only visits are down, creating new opportunities for co-selling complementary services. 

"We’re seeing one of the most significant shifts in medical aesthetic spending in recent years, with GLP-1 and weight loss medications now surpassing professional-grade skincare and ranking just behind energy-based devices and dermal fillers in non-surgical aesthetics," said Erika Sheyn, SVP of Aesthetics at Guidepoint Qsight, a provider of healthcare data and analytics. "This change highlights how patient priorities are expanding beyond traditional aesthetic treatments to include weight management as part of a holistic approach to appearance and wellness.”